Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35

Benzinga Newsdesk www.benzinga.com Positive 85.3%

Neg 0% Neu 0% Pos 85.3%

Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $32 to $35.